The CLIA Molecular Diagnostics Laboratory within the Cancer Research Technology Program will perform messenger RNA isolation and expression analysis specific to a 20-gene panel on formalin-fixed paraffin-embedded (FFPE) patient samples using the NanoString platform. This assay has been validated for clinical samples and allows for the identification of activated B-cell (ABC) and germinal center B-cell (GCB) subtypes of diffuse large B-cell lymphomas (DLBCL) to enable assignment to a therapeutic regimen. Total RNA from sections of FFPE material will be isolated with a minimum requirement of 62.5 ng to proceed with the assay. All assays will be performed with internal negative and positive control RNAs, in addition to both ABC and GCB control RNAs. An mRNA expression profile of each sample and control will be generated using a custom panel of capture probes and the NanoString lymphoma subtyping test. Samples will be classified as either ABC or GCB subtypes using an established predictor algorithm. All operations will be performed in a CLIA environment, and the CLIA Molecular Diagnostics Laboratory will provide a final report with the results with interpretations and conclusions. Sufficient basic consultation with a subject matter expert is included with the service.
More details about the assignment to a therapeutic regimen can be found in the following publication: